2
|
Shahrokh Z, Royle L, Saldova R, Bones J, Abrahams JL, Artemenko NV, Flatman S, Davies M, Baycroft A, Sehgal S, Heartlein MW, Harvey DJ, Rudd PM. Erythropoietin Produced in a Human Cell Line (Dynepo) Has Significant Differences in Glycosylation Compared with Erythropoietins Produced in CHO Cell Lines. Mol Pharm 2010; 8:286-96. [DOI: 10.1021/mp100353a] [Citation(s) in RCA: 58] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/14/2023]
Affiliation(s)
- Zahra Shahrokh
- Shire Human Genetic Therapies, Cambridge, MA, USA, Lonza Biologics, plc, Slough, U.K., NIBRT Dublin Oxford Glycobiology Laboratory, Conway Institute, University College Dublin, Belfield, Dublin 4, Ireland, and Glycobiology Institute, Department of Biochemistry, Oxford University, Oxford, U.K
| | - Louise Royle
- Shire Human Genetic Therapies, Cambridge, MA, USA, Lonza Biologics, plc, Slough, U.K., NIBRT Dublin Oxford Glycobiology Laboratory, Conway Institute, University College Dublin, Belfield, Dublin 4, Ireland, and Glycobiology Institute, Department of Biochemistry, Oxford University, Oxford, U.K
| | - Radka Saldova
- Shire Human Genetic Therapies, Cambridge, MA, USA, Lonza Biologics, plc, Slough, U.K., NIBRT Dublin Oxford Glycobiology Laboratory, Conway Institute, University College Dublin, Belfield, Dublin 4, Ireland, and Glycobiology Institute, Department of Biochemistry, Oxford University, Oxford, U.K
| | - Jonathan Bones
- Shire Human Genetic Therapies, Cambridge, MA, USA, Lonza Biologics, plc, Slough, U.K., NIBRT Dublin Oxford Glycobiology Laboratory, Conway Institute, University College Dublin, Belfield, Dublin 4, Ireland, and Glycobiology Institute, Department of Biochemistry, Oxford University, Oxford, U.K
| | - Jodie L. Abrahams
- Shire Human Genetic Therapies, Cambridge, MA, USA, Lonza Biologics, plc, Slough, U.K., NIBRT Dublin Oxford Glycobiology Laboratory, Conway Institute, University College Dublin, Belfield, Dublin 4, Ireland, and Glycobiology Institute, Department of Biochemistry, Oxford University, Oxford, U.K
| | - Natalia V. Artemenko
- Shire Human Genetic Therapies, Cambridge, MA, USA, Lonza Biologics, plc, Slough, U.K., NIBRT Dublin Oxford Glycobiology Laboratory, Conway Institute, University College Dublin, Belfield, Dublin 4, Ireland, and Glycobiology Institute, Department of Biochemistry, Oxford University, Oxford, U.K
| | - Steve Flatman
- Shire Human Genetic Therapies, Cambridge, MA, USA, Lonza Biologics, plc, Slough, U.K., NIBRT Dublin Oxford Glycobiology Laboratory, Conway Institute, University College Dublin, Belfield, Dublin 4, Ireland, and Glycobiology Institute, Department of Biochemistry, Oxford University, Oxford, U.K
| | - Mike Davies
- Shire Human Genetic Therapies, Cambridge, MA, USA, Lonza Biologics, plc, Slough, U.K., NIBRT Dublin Oxford Glycobiology Laboratory, Conway Institute, University College Dublin, Belfield, Dublin 4, Ireland, and Glycobiology Institute, Department of Biochemistry, Oxford University, Oxford, U.K
| | - Alison Baycroft
- Shire Human Genetic Therapies, Cambridge, MA, USA, Lonza Biologics, plc, Slough, U.K., NIBRT Dublin Oxford Glycobiology Laboratory, Conway Institute, University College Dublin, Belfield, Dublin 4, Ireland, and Glycobiology Institute, Department of Biochemistry, Oxford University, Oxford, U.K
| | - Surinder Sehgal
- Shire Human Genetic Therapies, Cambridge, MA, USA, Lonza Biologics, plc, Slough, U.K., NIBRT Dublin Oxford Glycobiology Laboratory, Conway Institute, University College Dublin, Belfield, Dublin 4, Ireland, and Glycobiology Institute, Department of Biochemistry, Oxford University, Oxford, U.K
| | - Michael W. Heartlein
- Shire Human Genetic Therapies, Cambridge, MA, USA, Lonza Biologics, plc, Slough, U.K., NIBRT Dublin Oxford Glycobiology Laboratory, Conway Institute, University College Dublin, Belfield, Dublin 4, Ireland, and Glycobiology Institute, Department of Biochemistry, Oxford University, Oxford, U.K
| | - David J. Harvey
- Shire Human Genetic Therapies, Cambridge, MA, USA, Lonza Biologics, plc, Slough, U.K., NIBRT Dublin Oxford Glycobiology Laboratory, Conway Institute, University College Dublin, Belfield, Dublin 4, Ireland, and Glycobiology Institute, Department of Biochemistry, Oxford University, Oxford, U.K
| | - Pauline M. Rudd
- Shire Human Genetic Therapies, Cambridge, MA, USA, Lonza Biologics, plc, Slough, U.K., NIBRT Dublin Oxford Glycobiology Laboratory, Conway Institute, University College Dublin, Belfield, Dublin 4, Ireland, and Glycobiology Institute, Department of Biochemistry, Oxford University, Oxford, U.K
| |
Collapse
|